Was Quang Pham’s Cadrenal Therapeutics (CVKD) share sale pre-planned?

Yes. The Form 4 states the 1,165-share sale was executed under a Rule 10b5-1 trading arrangement. This pre-arranged plan was adopted on September 25, 2025, meaning trades occur automatically under preset conditions rather than discretionary timing decisions.

Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 1,165 shares in pre-planned trade

Q: What price did Quang Pham receive for his Cadrenal Therapeutics (CVKD) share sale?

The Form 4 reports a weighted average sale price of $5.69 per share. Footnotes explain the 1,165 shares were sold in multiple transactions at prices ranging from $5.60 to $5.82, with the exact breakdown available on request to the company or regulators.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cadrenal Therapeutics CEO and Chairman Quang Pham reported an open-market sale of 1,165 shares of Common Stock on May 22, 2026 at a weighted average price of $5.69 per share, executed as an "S" code transaction.

The sale was made pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025, meaning it was pre-arranged. After the sale, Pham directly owns 194,924 shares of Cadrenal Therapeutics common stock and indirectly holds 20,000 shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power.

Insider Trade Summary 10b5-1

Net Seller: 1,165 shares ($6,629)

Net Sell 2 txns

Insider Pham Quang X

Role CEO and Chairman

Sold 1,165 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,165	$5.69	$7K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 194,924 shares (Direct, null); Common Stock — 20,000 shares (Indirect, The PVBQ Living Trust)

Footnotes (1)

Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.60 through $5.82. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

Key Figures

Shares sold: 1,165 shares Weighted average sale price: $5.69 per share Direct holdings after sale: 194,924 shares +1 more

4 metrics

Shares sold 1,165 shares Open-market sale on May 22, 2026

Weighted average sale price $5.69 per share Common Stock, multiple trades $5.60–$5.82

Direct holdings after sale 194,924 shares Common Stock held directly by Quang Pham

Indirect holdings after sale 20,000 shares Held via The PVBQ Living Trust

Key Terms

Rule 10b5-1 trading arrangement, weighted average price, open-market sale, indirect ownership, +1 more

5 terms

Rule 10b5-1 trading arrangement regulatory

"sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

""ownership_type": "indirect""

voting and dispositive power regulatory

"has sole voting and dispositive power with respect to the shares owned"

Form 4 Insider Transactions: What Each Field Means →

05/26/2026 - 09:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pham Quang X

(Last)

(First)

(Middle)

C/O CADRENAL THERAPEUTICS, INC.,

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA

FLORIDA

32082

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/22/2026		S		1,165⁽¹⁾	D	$5.69⁽²⁾	194,924	D
Common Stock								20,000	I	The PVBQ Living Trust⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.60 through $5.82. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Quang Pham	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cadrenal Therapeutics (CVKD) report for Quang Pham?

Cadrenal Therapeutics reported that CEO and Chairman Quang Pham sold 1,165 shares of common stock. The transaction occurred on May 22, 2026 as an open-market sale at a weighted average price of $5.69 per share, according to the Form 4 filing.

How many Cadrenal Therapeutics (CVKD) shares does Quang Pham hold after the sale?

After the reported sale, Quang Pham directly holds 194,924 shares of Cadrenal Therapeutics common stock. He also indirectly holds 20,000 additional shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power over those shares.

How are Quang Pham’s indirect Cadrenal Therapeutics (CVKD) holdings structured?

Pham’s indirect holdings consist of 20,000 Cadrenal Therapeutics shares owned by The PVBQ Living Trust. He is the trustee and has sole voting and dispositive power over these shares, while his child is identified as the sole beneficiary of the trust.